Creative Biolabs Echoes White House’s Efforts in Next-Generation COVID-19 Vaccine Development
Positive responses are made by Creative Biolabs upon hearing the White House's attempt to develop the next generation of vaccines for SARS-CoV-2 virus mutates.
New York, US (PRUnderground) August 30th, 2022
News reports that the Biden administration officials hold a summit discussing the lofty goal of the White House to develop the next-generation COVID-19 vaccines. This extensive initiative aims at novel immunization development to curb the infection or transmission of future SARS-CoV-2 variants. As one of the major forces in vaccine discovery and development, Creative Biolabs praises the new White House initiative and announces to actively cooperate with vaccine manufacturers and pharmaceutical companies who need professional CRO support in the next-generation COVID-19 vaccine research.
In line with the White House’s effort to develop a new vaccine that would prevent COVID-19 infection no matter how the virus mutates, Creative Biolabs allows scientists to develop different types of vaccines both at the preclinical and clinical stages.
Namely, SARS-CoV-2 vaccine services for novel immunization development at this leading biotech company include in silico vaccine design, live attenuated and killed vaccine development, recombinant subunit vaccine development, mRNA vaccine development, modified vaccinia virus vectored vaccine development, virus-like particles based vaccine development, SARS-CoV-2 DNA vaccine development. In addition to supporting vaccine development in the preliminary stage, Creative Biolabs is also an ideal partner for vaccine formulation optimization, analysis, and qualification.
“But actually new generation of COVID-19 vaccine development has languished for a shortage of funds, and it still faces scientific and political risks given the ever-changing variants.” A scientist from Creative Biolabs said. “Thus, efficient and timely diagnostics and antivirals remain the key to preventing serious illness and death before any new technologies are available for broad use.”
Molecular biology and immunology experts at Creative Biolabs leverage the advanced RNA imaging technology for SARS-CoV-2 test kit development, having helped global researchers develop in vitro diagnostic assays to detect COVID-19 infection by measuring the nucleic acid level and the antibody level. And even now, universal testing and screening remain helpful for the early isolation and treatment of infected people.
Indeed, Creative Biolabs actively participates not only in the development of vaccines and test kits for COVID-19 but is also a top player in antiviral drug discovery. For instance, the neutralizing antibody proves to be a target for developing therapeutic strategies, building on which several phage display libraries for SARS-CoV-2 have been established at Creative Biolabs to screen neutralizing antibodies to SARS-CoV-2.
Visit https://sars-cov-2.creative-biolabs.com to reach more supportive solutions to SARS-CoV-2 vaccine development, test kit development, and antiviral drug discovery.
About Creative Biolabs
Creative Biolabs headquartered in New York, US, is a global leader in providing CRO services for SARS-CoV-2 vaccine design, development, optimization, and qualification. The company is also involved in in vitro diagnostic (IVD) reagent development and novel drug discovery through cutting-edge technologies and facilities. Creative Biolabs delivers a wide range of products and protocols in past years to worldwide researchers to accelerate the fight against the COVID-19 pandemic.